# Leveraging genetic ancestry continuum information to interpolate PRS for admixed populations

Hull<sup>5,6</sup>, Buu Truong<sup>1,2,3,8</sup>, Whitney Hornsby<sup>1,2</sup>, Haoyu Zhang<sup>7</sup>, Nilanjan Chatterjee<sup>9,10</sup>, Pradeep Natarajan<sup>1,2,3,6</sup> Yunfeng Ruan<sup>1</sup>, Rohan Bhukar<sup>1,2</sup>, Aniruddh Patel<sup>1,2,3</sup>, Satoshi Koyama<sup>1,2,3,4</sup>, Leland

#### Affiliations:

1

2 3

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28 29

30

34

35 36

37

38

39 40 41

- 1. Program in Medical and Population, Genetics and Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA, USA
- 2. Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA
- 3. Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA. USA
- 4. Laboratory for Cardiovascular Genomics and Informatics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
- 5. Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA
- 6. Department of Medicine, Harvard Medical School, Boston, MA, USA
- 7. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
- 8. Department of Genetic Epidemiology and Statistical Genetics, Harvard T.H. School of Public Health, Cambridge, MA, US
- 9. Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
- 10. Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
- Please address correspondence to:
- Pradeep Natarajan, MD MMSc
- 31 185 Cambridge Street, CPZN 5.238
- 32 Boston, MA 02446
- 33 617-726-1843
  - pnatarajan@mgh.harvard.edu

#### Funding:

P.N. is supported by NHGRI U01HG011719 and NHLBI R01HL127564. N.C is supported by NHGRI U01HG011719 and R01HG010480.

#### Disclosures:

- 42 P.N. reports research grants from Allelica, Amgen, Apple, Boston Scientific,
- 43 Genentech / Roche, and Novartis, personal fees from Allelica, Apple, AstraZeneca,
- 44 Blackstone Life Sciences, Creative Education Concepts, CRISPR Therapeutics, Eli
- 45 Lilly & Co, Esperion Therapeutics, Foresite Capital, Foresite Labs, Genentech /
- Roche, GV, HeartFlow, Magnet Biomedicine, Merck, Novartis, TenSixteen Bio, and 46
- 47 Tourmaline Bio, equity in Bolt, Candela, Mercury, MyOme, Parameter Health,
- 48 Preciseli, and TenSixteen Bio, and spousal employment at Vertex Pharmaceuticals,
- 49 all unrelated to the present work.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# **Abstract**

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95 96 97

98

Calculating optimal polygenic risk scores (PRS) across diverse ancestries. particularly in admixed populations, is necessary to enable equitable genetic research and clinical translation. However, the relatively low representation of admixed populations in both discovery and fine-tuning individual-level datasets limits PRS development for admixed populations. Under the assumption that the most informative PRS weight for a homogeneous sample, which can be approximated by a data point in the ancestry continuum space, varies linearly in that space, we introduce a Genetic Distance-assisted PRS Combination Pipeline for Diverse Genetic Ancestries (DiscoDivas) to interpolate a harmonized PRS for diverse, especially admixed, ancestries, leveraging multiple PRS weights fine-tuned within singleancestry samples and the genetic ancestry continuum information. DiscoDivas treats ancestry as a continuous variable and does not require shifting between different models when calculating PRS for different ancestries. We generated PRS with DiscoDivas and the current conventional method, i.e. fine-tuning multiple GWAS PRS using the matched or similar ancestry sample, for simulated datasets and large-scale biobank datasets (UK Biobank [UKBB] N=415,402, Mass General Brigham Biobank N=53,306, All of Us N=245,394) and compared our method with the conventional method with quantitative traits and complex disease traits. DiscoDivas generated a harmonized PRS of the accuracy comparable to or higher than the conventional approach, with the greatest advantage exhibited in admixed samples: DiscoDivas PRS for admixed samples was more statistically accurate than the PRS fine-tuned in matched or similar ancestry sample in 12 out of 16 simulated scenarios and was statistically equivalent in the remaining four scenarios; when tested with quantitative trait data in UKBB, DiscoDivas increased the PRS accuracy of admixed sample by 5% on average; yet no statistical difference was observed when tested for binary traits in UKBB where ancestry-matched data was available. For the single ancestry samples, the accuracy of DiscoDivas PRS and PRS fine-tuned in match samples was similar. In summary, our method DiscoDivas yields a harmonized PRS of robust accuracy for individuals across the genetic ancestry spectrum, including where ancestry-matched training data may be incomplete.

# Introduction/Main

Individuals not of European ancestry remain underrepresented in GWAS, which at least partly explains why PRS performance is generally reduced among those of non-European versus European ancestry<sup>1</sup>. Within the constraints of existing data, the current principal solution to increase the PRS accuracy among non-European individuals is to fine-tune a combination of PRS derived from multiple populations or multiple traits with the individual-level data of a validation sample<sup>2–6</sup>. However, PRS accuracy decays as the genetic distance between the testing and validation samples increases<sup>7</sup>. Relative to the vast diversity across the genetic ancestry continuum, the existing and near-term individual-level datasets that can be used for fine-tuning PRS combinations remains very sparse. Most existing individual-level genotype data are mainly collected from single-ancestry populations and therefore admixed populations are left underrepresented and largely unaddressed <sup>8–11</sup>. Additionally, testing and validation samples that are labeled as "from the same superpopulation" are often truly genetically heterogeneous <sup>10,12–15</sup>, leading to variable accuracy within such samples.

PRS analysis across diverse ancestries may also be limited by inconsistency. The raw PRS distributions of the same model varies by ancestry and therefore the raw PRS values for individuals of different genetic ancestries should not be directly compared without ancestry correction <sup>16-18</sup>. Although prior research <sup>16,18,19</sup> has shown that regressing out the top principal components of ancestry (PCA) from the PRS can unify the PRS distributions of different ancestries (i.e., the mean and standard deviation of corrected PRS sampled from different populations can become very close), the inconsistency is only partially solved. In the application of PRS across diverse ancestries, one would have to use one PRS model for all the individuals, causing inconsistent PRS accuracy, or use several discrete PRS models for different individuals approximating superpopulations causing inconsistent PRS modelling and accuracy.

Given these issues and the increasing clinical use of PRS<sup>20–22</sup>, PRS generation for diverse genetic ancestries with more consistent accuracy and more unified PRS distributions is critically needed. We devised a method, DiscoDivas, a Genetic Distance-assisted PRS Combination Pipeline for Diverse Genetic Ancestries, to generate PRS across the genetic ancestry continuum. This method is based on the recent observation<sup>7</sup> that the PRS accuracy in the testing data decays approximately linearly as the genetic distance between the testing and validation samples increases, and that the genetic distance can be approximated by Euclidian distance of PCA based on the global ancestries<sup>7</sup>. Based on this observation, we assumed that the most informative PRS weights for a sample can be linearly interpolated from the currently available PRS weights that are fine-tuned in the ancestries surrounding it in the global ancestry-based PCA space with the interpolation weights based on the Euclidian distance of the PCA. In summary, DiscoDivas calculates PRS for diverse genetic ancestries whose genetic data may not be sufficiently powerful to train the PRS model by linearly interpolating the multiple PRS fine-tuned in ancestries whose genetic data are more available. We evaluated its performance in simulated and empiric data.

# Results

99

100

101

102

103 104

105

106

107

108

109

110

111

112

113 114

115

116

117

118 119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141 142

143

144

145

146

## Overview of DiscoDivas

DiscoDivas combines PRS fine-tuned in different validation samples - generally from different single-ancestry populations - to linearly interpolate PRS for individuals of diverse genetic ancestries, treating the ancestry information as a continuous variable. The rationale for PRS combination is based on the observation that the correlation of the most informative PRS weight for two samples of different ancestry drops as the genetic distance, represented by Euclidean distance of global ancestry-based PCA, increases<sup>7</sup>. Therefore, the best PRS weight for an ancestry representation can be linearly interpolated from other PRS weights fine-tuned in other ancestries with the additional consideration of the genetic distance between the samples.

Under the same principle of interpolating the PRS weight, the best PRS can be interpolated from several PRS calculated using the weight fine-tuned in other ancestries. Since generating individual-specific PRS weights in a testing dataset causes redundant calculation and given the difficulty of normalizing information from different datasets, we combine the PRS instead of the SNP weights. The PRS of

individuals in the testing sample is a linear combination of PRS based on the SNP weights fine-tuned in different validation samples:

$$PRS_i = \sum w_{i,k} PRS_{i,k}$$

where  $PRS_{i,\,k}$  is the PRS of testing individual i calculated using the weight fine-tuned in validation sample k;  $w_{i,\,k}$  is the combination coefficient mainly based on the reciprocal of the PCA Euclidean distance between the testing individual and median point of validation sample  $D_{i-k}$ . Note that the input PRS and PCA should be of the same scale: all the individuals are projected to the same PCA space based on a global ancestry reference panel and the PRS input  $PRS_{i,\,k}$  is the raw PRS regressed out the top PCs and then standardized.

In addition to the PCA distances, other factors are included in the model. First, since some fine-tuning samples are more correlated than others (e.g., EAS and SAS are more correlated than AFR and EUR), the combination coefficients should be further modified by these correlations, which can also be extracted from the PCA Euclidean distances. Second, since PRS fine-tuned in each of the validation samples may be of differing qualities (e.g., when the PRS model fine-tuned in different samples are based on GWAS of different sample sizes or populations), the quality of the PRS trained with each of the training data will vary and should be taken into account when combining the PRS. Thus, the combination coefficient  $w_{i,\,k}$  in the previous formula is a function of multiple factors:

$$w_{i,k} = f\left(\frac{1}{D_{i-k}}, G, r_k\right)$$

where  $\frac{1}{D_{i-k}}$  is the reciprocal of PCA Euclidean distance between the individual i and the validation sample k; G is the matrix of PCA Euclidean distance between validation samples;  $r_k$  is the parameter describing the quality of validation samples. A more detailed description of implementing DiscoDivas is given in the Method session.

## Overview of multi-population GWAS PRS model




Figure 1: The workflow of comparing DiscoDivas with the existing method.

Left: The ideal situation for the existing method is to fine-tune a PRS model that contains multiple GWAS with matched validation data, which is not currently available for many under-represented populations. Right: DiscoDivas first fine-tunes the PRS in the available ancestries, which are currently AFR, EAS, EUR, and SAS, and interpolates PRS for diverse ancestry groups based on these fine-tuned

PRS. In this plot, POP refers to any ancestry for which the PRS is to be calculated.

181

182 183

184

185 186

187

188

189

190 191

192

193

194

195

196

197

198

199

200

201

202

203

204 205

206 207

208

209

210 211

212

213

214

215

216

217

218

219

220 221

222

223

224

225

226

227

228

229

230 231

A common approach for constructing PRS is to include as much genome-wide association study (GWAS) summary statistic data as possible in the discovery data<sup>5,23,24</sup>. The GWAS data is typically then processed by PRS methods that will adjust the SNP effect size using a set of hyper-parameters. Individual-level data of an independent validation sample is used to fine-tune the hyper-parameters across PRS methods and the combination of the fine-tuned PRS. The resulting PRS is expected to perform the best in samples of matched ancestry with the validation sample.

The current approach, as shown in the left panel of Figure 1, is to use the multi-GWAS PRS fine-tuned in the matched sample or the closest approximation when the matched sample is unavailable. The pipeline of adjusting SNP effect sizes and combining information from different GWAS varies widely. Without loss of generality, we built the following pipeline as a representation of the current conventional method: we first adjusted the SNP effect size of each of the summary statistical GWAS datasets by a Bayesian method and then chose the most predictive PRS from all the PRS generated under different hyper-parameters. For simulated GWAS data, we used PRS-CS<sup>25</sup> to adjust the SNP effect size and LDpred2<sup>26</sup> for real GWAS. Then we used the validation data to first select the most predictive PRS based on each GWAS and then to train the linear combination of the most predictive single-GWAS PRS with a linear regression model. The final PRS model generated from each of the validation datasets is a linear combination of PRS. For the empiric data set, the PRS were fine-tuned controlling for the following covariates: top 20 PCA, sex, and age. We used AFR, EAS, EUR, SAS, AMR, and admixed samples to fine-tune the PRS.

On top of the conventional method, DiscoDivas calculates PRS of any ancestry using a linear combination of a group of PRS fine-tuned in currently available samples as shown in the right panel of Figure 1. The PRS input for DiscoDivas in this study was the multi-GWAS PRS fine-tuned in AFR, EAS, EUR, and SAS validation samples with the conventional method pipeline as mentioned above. The interpolation of these four PRS is based on the PCA calculated using the 1000 Genomes reference panel. For most of the PRS analysis conducted in in the present study, the input PRS of DiscoDivas are based on the same set of discovery GWAS and the validation datasets are sufficiently large to generate a stable result. Therefore, we assumed that all the input PRS can be viewed as of equal quality and their parameter for PRS quality  $A_k$  can be viewed as a constant value in the present study.

## Simulated data results

Summary-level GWAS used as discovery data were generated based on simulated genotype data based on 1000 Genomes reference as described in the previous publication provided by Zhang et al<sup>6</sup>. The phenotypes were based on 100, 300, 1,000, or 10,000 causal SNPs randomly selected from the 1.4 million Hapmap3 SNPs to represent traits of different polygenicity. The per-allele effect sizes of the causal SNPs followed a normal distribution, and the heritability was set as 0.6. Scenarios where both casual SNPs and effect sizes were constant across the populations and where the casual SNPs were shared but the effect sizes varied across the populations were simulated. We used up to 100,000 simulated individuals from AFR, EAS, EUR, and SAS to generate the discovery summary statistic GWAS dataset with PLINK2<sup>27</sup> and left the remaining samples out for other downstream analyses.

Validation and testing samples were also simulated based on UKBB genotype data with the phenotypes simulated using the same pipeline and parameters as described above. UKBB participants were divided by genetic ancestry using 1000 Genomes as a reference. In addition to the groups of AFR, EAS, EUR, SAS, and AMR whose PCA information were matched with the 1000 Genomes reference, we identified the group of "to-be-determined" (tbd) for admixed individuals whose PCA information was not matched with any of the five ancestries by definition. From each ancestry group, 1.3k individuals were used as the validation datasets (See section entitled 'Simulated data' in Methods). The SNP effect sizes from the discovery GWAS data were adjusted using PRS-CS with the default parameters, fine-tuned, then combined using the validation data based on 1.3k UKBB-based individuals per population and tested in the rest of the UKBB-based individuals. The process of selecting causal SNPs, assigning effect size, simulating phenotype data, and the downstream GWAS and PRS analysis was repeated 20-fold.

We primarily focused on the PRS performance in the admixed testing sample. DiscoDivas, which is based on PRS fine-tuned in AFR, EAS, EUR, and SAS, was compared with the conventional PRS fine-tuned in the matched admixed validation sample in scenarios of different causal SNP numbers, different discovery GWAS sample sizes, and different causal SNP distribution across ancestry (See Figure 2)




Figure 2 Relative R² increase of DiscoDivas over the conventional PRS fine-tuned in a matched sample when tested in admixed individuals. The x-axis shows the simulated number of causal SNPs. The horizontal bar shows the mean relative R² increase and the color of the horizontal bar indicates the *p*-value of the paired t-test of DiscoDivas PRS R² and conventional PRS R², with cyan being *p*-value<0.005, dark blue being *p*-value<0.05 and grey being *p*-value>0.05. In panels a, b, and c, the causal SNP effect sizes are constant across different populations. The annotation texts on the top of each panel shows the sample size of discovery GWAS of different populations and the distribution of causal SNP effect sizes.

Although the comparison between DiscoDivas and the conventional method of fine-tuning PRS with matched ancestry sample in a single test iteration usually showed no statistical significance due to the small numeric differences, the paired t-test of DiscoDivas R² and the conventional PRS R² over the 20 iterations better clarified significant differences. When effect sizes of causal SNPs were constant across different ancestries (Figure 2 panel a, b, and c), the PRS generated by DiscoDivas had comparable accuracy with the PRS fine-tuned using matched data. We noticed that when the sample size of non-European discovery GWAS dropped and the dataset was relatively more Eurocentric, the advantage of DiscoDivas became less

statistically significant. In Figure 2 panel d, we compared DiscoDivas and the conventional PRS method of fine-tuning the PRS with matched ancestry in the scenario where causal SNPs were shared across all populations, but the effect sizes varied linearly in the PCA space. The advantage of DiscoDivas over conventional PRS method was more obvious in this scenario than when the effect sizes were constant across populations (Figure 2 panel a and d), presumably because personalized PRS combination with DiscoDivas better captured the changing effect sizes for the admixed testing sample. In all the scenarios tested, the advantage of DiscoDivas was least statistically significant when the number of causal SNPs was 10,000 but still significant when the number of causal SNPs was 1,000. Notably, the accuracy of both DiscoDivas and the conventional PRS method was the lowest when the number of causal SNPs was 10,000 (Supplementary Figure 1), indicating that the difference of the two PRS methods became less obvious when the input data became increasingly underpowered.

When predicting the individuals that are usually classified as single ancestries, i.e. AFR, EAS, EUR, and SAS, DiscoDivas showed no statistically significant difference or a slight advantage over the conventional PRS method (Supplementary Figure 2). When predicting AMR individuals, we used admixed validation data (tbd) to fine-tune the conventional PRS due to the small sample size of the AMR dataset. The PRS performance when testing in the AMR dataset was similar as in admixed data but the statistical significance was weaker, potentially due to the small sample size and the high heterogeneity of the AMR dataset. In general, DisocDivas showed its clearest advantage over the conventional method of fine-tuning PRS with matched PRS when the testing data and the validation data for the conventional method were of different ancestries.

## Sensitivity tests

Since the quality of validation data is essential to the performance of DiscoDivas, we evaluated the influence of minor missing information or alternative choices of validation data with the following tests:

First, we considered the possible scenario where PRS weights for different ancestries are provided from a publication but key detailed information about the validation data was not fully available, especially the PCA information of the validation datasets. A convenient approximation of the PCA of validation datasets is the median PCA value of the 1000 Genome<sup>28</sup> individuals of a certain ancestry or "superpopulation." Based on the simulation test as mentioned above, we tested the influence of replacing the actual PCA of the UKBB validation datasets with the 1000 Genome approximate on the 1) PCA Euclidean distance, 2) combination coefficient for interpolation, and 3) the PCA accuracy.

Since the UKBB individuals were selected to be included in validation datasets based on the PCA information of the 1000 Genomes, the PCA distribution of UKBB validation datasets closely aligned with that of the 1000 Genomes reference (Supplementary Figure 3). PCA distances between the testing individuals and the median point of validation datasets based on the actual UKBB validation data were highly correlated with the PCA distances based on the 1000 Genome approximation for all the testing ancestry groups AFR, AMR, EAS, EUR, SAS, and admixed ("tbd"), with the data residing within the highly overlapped intervals and the correlation of individual datapoints close to 1 (Supplementary Figure 4). The combination

coefficients were calculated assuming that the PRS weights fine-tuned in the four validation datasets, i.e. AFR, EAS, EUR, and SAS, were of equal quality. According to the formula in Method session,  $w_{i,k}$ , the combination coefficient of weighting the PRS fine-tuned in validation sample k for individual i, should be  $w_{i,k} \equiv \frac{1}{D_{i-k}} d_k$ , with the  $D_{i-k}$  being the PCA distance between individual i and the median point of sample k;  $d_k$  being the adjustment coefficient for PRS fine-tuned in sample k based on the distance between the validation samples.  $w_{i,k}$  was compared between the two scenarios of using the actual UKBB validation datasets versus using the 1000 Genomes approximate. The correlation of the combination coefficients was lower than the correlation of the PCA distance, especially for SAS testing individuals. However, each combination coefficient remained in almost the same range and the PRS fine-tuned in the SAS sample still had the highest weights (Supplementary Figure 5). When testing with the simulated data, the PRS R<sup>2</sup> had almost identical distribution and correlation > 0.99 with the R<sup>2</sup> of PRS based on the actual PCA information in all the simulated scenarios including when the causal SNP effect size varied with the ancestries (Supplementary Figure 6). The high similarity of the PRS accuracy despite the difference in combination coefficient might partly result from the correlation of the PRS fine-tuned in different samples and the constant combination coefficient range.

In addition, we tested if the results of DiscoDivas would remain robust for admixed individuals when using a different set of validation datasets. In addition to the primary simulation test where the validation datasets were simulated data based on UKBB genotype, PRS were fine-tuned with the left-out simulated datasets that were independent from the discovery GWAS while other parts of the analysis pipeline remained the same. The simulated AMR dataset was used to fine-tune PRS for AMR and admixed (tbd) testing samples for the conventional method. The PRS R<sup>2</sup> based on the two sets of validation datasets were compared in the scenarios where the discovery GWAS was based on 100k AFR, EAS, EUR, and SAS, and where the causal SNP effect sizes were constant across different ancestries. The correlation of PRS R<sup>2</sup> based on UKBB-based validation datasets and purely simulated validation datasets of DiscoDivase was larger than 0.99 in at scenarios, much higher than that of conventional PRS method, which ranged from 0.73 to 0.98 (Supplementary Figure 7). The advantage of DiscoDivas over the conventional PRS method showed a similar pattern (Supplementary Figure 8)

#### Biobank data results

324

325

326

327

328 329

330 331

332

333

334

335

336

337

338

339

340

341

342

343 344

345

346

347

348

349

350

351

352

353

354

355

356 357

358

359

360

361 362

363

364

365

366 367

368

369

370

371

372

373

374

We downloaded publicly available summary statistical data of body-mass index (BMI), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), total cholesterol (TC), triglycerides (TG), systolic blood pressure (SBP), diastolic blood pressure (DBP), coronary artery disease (CAD), and diabetes mellitus (DM2) and adjusted the SNP effect size using LDpred2 as described previously<sup>5</sup>.

For the quantitative traits, we used the validation samples of AFR, EAS, EUR, SAS, and admixed ("tbd") ancestry to fine-tune the model. The remaining UKBB samples were used as the testing data. The results for empiric quantitative trait data were highly aligned with the simulation results (Figure 4): DiscoDivas showed a robust advantage over the conventional PRS method of fine-tuning PRS with matched or similar ancestry samples when compared across the 7 traits in the admixed testing dataset. When predicting AFR, EAS, EUR, and SAS, DiscoDivas and the conventional PRS method had similar performance. The results of both methods in

AMR testing dataset had large deviations due to the small sample size and greater genetic heterogeneity of the AMR data.




Figure 3 Relative R<sup>2</sup> increase of DiscoDivas over the conventional PRS fine-tuned in a matched sample. The x-axis shows the population in which the PRS was tested. We used "tbd" as the fine-tuning dataset for the test in both tbd and AMR due to the absence of matched AMR validation data. The horizontal bar shows the mean of relative increase and the line-type of the bar indicates the *p*-value of paired t-test of DiscoDivas PRS R<sup>2</sup> and conventional PRS R<sup>2</sup>, with the solid bar being *p*-value <0.05 and dotted bar being *p*-value>0.05

For the binary traits coronary artery disease (CAD) and type 2 diabetes (DM2) (Figure 4), we used the AFR, EAS, EUR, SAS, AMR, and OTH (i.e., unclassified) samples from AoU as the fine-tuning data and tested in AFR, EAS, EUR, SAS, and tbd individuals in UKBB and AFR, EAS, EUR, SAS, and AMR individuals in MGBB. The DiscoDivas PRS were based on the PRS fine-tuned in AFR, EAS, EUR, and SAS and used the default assumption that the PRS fine-tuned from all the samples were of similar quality even though the sample sizes of both discovery GWAS and the fine-tuning samples were not balanced across different ancestries. AMR in UKBB was excluded because of the small sample size (N=669).

The PRS fine-tuned in different single samples and the DiscoDivas PRS had similar performances. It also appeared that some of the validation sample could be underpowered: generally, we expect the PRS fine-tuned in the matched sample to perform the best in the testing samples, but PRS fine-tuned in larger validation data performed better than PRS fine-tuned in smaller validation data in general. For example, the PRS fine-tuned in EAS AoU data performed worse than other PRS in both MGBB and UKBB EAS data and had low accuracy in other testing data as well; the CAD PRS fine-tuned in EUR performed better than all the other PRS in all the testing data and the effective sample size of EUR CAD validation data was much larger than all the other validation data.




Figure 4 PRS performance for coronary artery disease (CAD) and type 2 diabetes (DM2) tested in UKBB and MGBB. The plot shows OR per SD with the error bar showing 95% CI. The sub-panels show that population of the testing sample and the different colors show the method for generating the PRS, either fine-tuning in a single sample or combining the PRS using DiscoDivas.

# **Discussion**

413

414

415

416

417

418

419

420

421

422

423

424

425 426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446 447 448

449

450

451

452

453

454

455

456

457

458 459

460

461

462

463

We propose a new method, DiscoDivas, to interpolate the PRS for diverse, especially admixed, ancestries with a generalized framework that does not requiring binning into discrete ancestries. Our results shows that the accuracy of DiscoDivas was comparable to or greater than the conventional method, i.e. fine-tuning using the matched population sample when available. In addition, when generating PRS for a wide range of ancestries, DiscoDivas did not require shifting from several sets of PRS weight fine-tuned in discrete samples while remaining matched with the ancestry information. Our method provides a new solution to generate PRS for underrepresented, generally admixed, populations and as well as generate a harmonized PRS model across different ancestries.

The performance of our method depends on the quality of both the discovery GWAS data and the validation data. As shown in the simulation test, discovery GWAS datasets that represent diverse ancestries with sufficient sample size will increase the accuracy of interpolated PRS generated by DiscoDivas. On the contrary, Eurocentric and underpowered discovery GWAS datasets would limit the advantage of DiscoDivas over the conventional PRS method. This might partly explain the limited advantage of DiscoDivas when predicting binary traits: the discovery GWAS datasets were highly Eurocentric and the GWAS, especially the non-European ones, could be more underpowered than quantitative trait GWAS. Furthermore, the PRS fine-tuned in validation datasets of insufficient sample size will be overfitted and cannot be used to fairly evaluate the performance of either the conventional PRS method or DiscoDivas. We aimed to address this issue by only using traits that 1) had effective sample sizes larger than 200 in all the validation samples, and 2) had high-quality phenotyping data in both the validation datasets and the testing datasets, However, Asian populations were largely under-represented in the current public biobanks: the effective sample size of many binary traits in EAS or SAS can be as small as <200 even in AoU, the most diverse and large-scale largely publiclyavailable biobank we had access to. This limited our choice for binary traits to only CAD and DM2. One additional limitation of our method is that DisoDivas does not consider the local ancestry information, which improve PRS predictions in various research<sup>24,29,30</sup>, especially PRS prediction of newly admixed populations<sup>31</sup>.

Our research underscores the notion that non-European populations, both admixed and singe-ancestry populations, remain largely under-represented in the existing genetic data. Furthermore, some potential extensions of our method will not become possible until we collect more diverse and larger datasets. First, our method has not been designed nor tested for extrapolating data, e.g. generating PRS for continental African samples based on African American, European, and Asian samples. Even though it is mathematically plausible to alter our method to extrapolate the PRS, we lack data such as continental African samples to test the method. Secondly, we currently only consider the assumption that the most informative genome-wide PRS weight shifts linearly in the PCA space. Although more complicated PRS interpolation, e.g. interpolation guided by local ancestry information <sup>24,29,30</sup>, pathwayspecific<sup>32,33</sup> and annotation-guided<sup>34</sup> PRS weights and polynomial interpolation<sup>35,36</sup>, can possibly further improve the PRS accuracy, training such complicated models would require collecting much larger and more diverse datasets than the existing data. Finally, additional biological insights could be revealed by interpolating PRS if genetic data of all the involved diverse ancestries are of sufficient power. In this case,

the differences between interpolated PRS and the PRS trained using the matched ancestry would indicate the population- or sample- specific factors absent in the interpolation model, e.g. population-specific genetic variance<sup>37</sup>, complicated population stratification involving cofounding factors<sup>38,39</sup>, sample/ancestry-specific modifiers like local adaptation<sup>38</sup>, gene x environment interactions<sup>40</sup> or other factors that contribute to the genetic variant frequency or effect size in these samples/ ancestries.

In conclusion, our method provides a new option to treat the ancestry information as a continuous variable and interpolate a harmonized PRS for diverse ancestries. Notably, although our method was developed primarily to calculate PRS when the matched validation datasets were unavailable, our research showed that successfully interpolating PRS required sufficient input data and highlighted the need to collect genetic data for underrepresented populations. We believe that more diverse and larger data collected in the coming future will enable the development of new methods of interpolating PRS and the elucidation of the genetic basis of complex traits.

# **Methods**

## DiscoDivas

DiscoDivas interpolates PRS of testing individuals of diverse ancestry according to the testing individual's PRS calculated using the PRS weight fine-tuned in other validation datasets and genetic distance information. The pipeline consists of two parts: harmonizing the input PRS data and interpolating the PRS.

#### **Data harmonization**

To reduce the bias in the interpolation, the PRS and PCA information should be in a unified and harmonized scale. First, all the individuals in the validation datasets and the testing dataset are projected in the same PCA space based on balanced reference data covering the global genetic ancestry continuum. The reference data is essential to avoid a skewed correlation between the similarity of the genotype and the genetic distance and ensure that the PCA Euclidian distance can present consistent genetic distance. The results presented in this study were based on PCA calculated using pruned SNPs of 1000 Genomes<sup>28</sup> samples. A detailed description of calculating PCA and Euclidian distance in this research is provided in the section entitled 'Calculation of 1000 Genomes-based PCA and Euclidean distance.'

Second, all the PRS input should be transferred to a comparable scale. We regressed out the top 10 PCs from the PRS and then standardized the PRS residuals to mean = 0 and standard deviation =1.

#### PRS interpolation

The overall mathematical model of DiscoDivas is a linear combination of PRS based on the weight fine-tuned in different validation datasets:

$$PRS_i = \sum a_i w_{i,k} PRS_{i,k}$$

where  $PRS_{i,k}$  is the normalized PRS of individual i trained in validation dataset k;  $w_{i,k}$  is the combination weight which is a function of genetic distance between the individual i and dataset k and other factors.  $a_i$  is a constant for individual i so that  $\sum a_i \ w_{i,k} = 1$ .

The essential factor contributing to  $w_{i,\,k}$  is the reciprocal of  $D_{i-k}$ , the genetic distance between individual I and dataset k, so that the interpolation is basically linear. In the ideal situation where all the validation samples are independent and generate PRS of the same level of accuracy, the genetic distance between the testing individuals and validation datasets is the only contribution factor and we define:

$$w_{i,k} \equiv \frac{1}{D_{i-k}}.$$

However, considering the more realistic scenarios where the validation samples can be correlated and the PRS trained from different validation datasets can be of different accuracy, we introduce two parameters:

- 1)  $d_k$ : tuning parameters based on the genetic distance / correlation between the training datasets.
- 2)  $r_k$ : tuning parameter that represent the accuracy of the PRS fine-tuned in sample k;

so that the overall combination weight is

$$w_{i,k} \equiv \frac{1}{D_{i-k}} d_k r_k$$

The final model of DiscoDivas is

$$PRS_i = \sum a_i \frac{1}{D_{i-k}} d_k r_k PRS_{i,k}$$

Here we propose the default method for calculating  $d_k$  and  $r_k$ :

 $d_k$  is based on the genetic distance matrix G in which each row and column represent a validation sample, and the element is genetic distance between the samples, with diagonal ones being zero. The shrinkage follows the similar principle of correcting marginal SNP effect size by inversing the LD matrix, except that the correlation between the shrinkage in this step  $d_k$  and other factors like the genetic distance between individuals in the testing data and the validation sample  $D_{i-k}$  and the accuracy of the PRS fine-tuned in the validation sample, the vector of shrinkage parameter  $d_k$  is only derived from  $G^{-1}$ :

$$\vec{d} = G^{-1}\vec{1}$$

, where  $\vec{1}$  is a vector of the same length as  $\vec{d}$  and with all the elements being 1.  $r_k$  is based on the accuracy of the PRS fine-tuned in the sample k. Theoretically, a PRS based on common SNPs can explain all the heritability contributed by common SNPs under the additive assumption. Under this scenario, the PRS  $R^2$  is close to the heritability  $h^2$ , and the PRS is saturated (namely, adding more samples in the Discovery GWAS would further increase the PRS accuracy if other conditions remain the same). Previous research used percentage of heritability explained to present the accuracy of the PRS so that PRS predicting traits of different heritability and binary traits of different prevalence can be compared directly. Here we recommend using common SNP heritability explained as the first choice of  $r_k$  if the heritability of the target trait in the validation samples or a larger sample but is homogenous with the validation sample is available:

$$r_k = \sqrt{\frac{R_{PRS}^2}{h^2}}$$

If  $h^2$  is unknown, we provided an alternative approach that approximates the PRS

given the fact that most of the PRS is far from saturation and the accuracy of the PRS is roughly linearly correlated with the sample size of the discovery GWAS  $N_k$ , we combine the information from different samples in a similar way by combining Z scores in fixed-effect size meta-analysis:

556

557

558 559

560

561

562

563

564

565

566 567

568

569

570 571

572

573 574

575

576

577

578

579

580 581

582

583

584 585

586

587 588 589

590

591 592

593

594

595

596

597

598

599

600 601

602

603

604

$$r_k = \sqrt{N_{k \ discovery}}$$

If the trait used in the discovery GWAS is not the same for all the validation data, the accuracy of the PRS for predicting the target traits also depends on the heritability of the trait in the discovery GWAS  $h_{k \, discovery}^{2}$  and the genetic correlation between the discovery GWAS trait and the target trait  $rg_{k\;discovery-target}$ 

$$r_k = \sqrt{N_{k \, discovery} * h_{k \, discovery}^2 * rg_{k \, discovery-target}}$$

In a common scenario where discovery data come from multiple GWAS from different ancestries and of decent statistical power for each ancestry yet the heritability of the target trait in the validation sample is unknown or cannot be accurately estimated, the accuracy of the PRS fine-tuned in each single-ancestry validation sample is hard to estimate but is likely of similar accuracy. Therefore  $r_k$ can be omitted, or equivalently set to a default constant value of 1.

In the DiscoDivas script provided, the  $r_k$  is set to be the default value 1 unless defined by the user otherwise,  $a_i$ ,  $D_{i-k}$ ,  $d_k$  is automatically calculated from the PCA information provided by the user.

## Constructing PRS with single fine-tuning sample

The PRS were derived from multiple GWAS conducted in different populations. GWAS data were first processed with PRS-CS or LDpreds2 to generate adjusted SNP weight: Hapmap3 SNP were first extracted from each GWAS as the input for the PRS method. The PRS methods were performed using default parameters: For PRS-CS, parameters of the prior distribution were set to phi = 1, 10<sup>-2</sup>, 10<sup>-4</sup>, 10<sup>-6</sup>, a = 1, b = 0.5 and the parameters of Markov Chain Monte Carlo (MCMC) were total number of MCMC iterations = 1000, number of burn-in = 500, thinning factor of the Markov chain = 5. For LDpred2, the parameter were the default set as in previous research<sup>5</sup>: proportion of variants assumed to be causal was  $1.0 \times 10^{-4}$ .  $1.8 \times 10^{-4}$ .  $3.2 \times 10^{-4}$ ,  $5.6 \times 10^{-4}$ ,  $1.0 \times 10^{-3}$ ,  $1.8 \times 10^{-3}$ ,  $3.2 \times 10^{-3}$ ,  $5.6 \times 10^{-3}$ ,  $1.0 \times 10^{-2}$ ,  $1.8 \times 10^{-2}$ ,  $3.2 \times 10^{-2}$ ,  $5.6 \times 10^{-2}$ ,  $1.0 \times 10^{-1}$ ,  $1.8 \times 10^{-1}$ ,  $3.2 \times 10^{-1}$ ,  $5.6 \times 10^{-1}$  and 1, the scale of heritability was 0.7, 1 and 1.4 times of the estimated heritability, with options of whether allowing a sparse output or not.

Each set of parameters generated a corresponding set of adjusted SNP weight, which were then used to calculate PRS in the fine-tuning samples. The most predictive PRS for each GWAS was selected based on a linear or logistic regression model predicting the phenotype using the PRS and adjusting for top 10 PCs, age. sex information and genotyping batch for biobank empirical analyses, and adjusting for only top 10 PCs for simulated analyses. For All of Us data, sex information combined assigned sex and self-reported gender to capture inclusiveness in data collection.

To generate the final PRS weight, multiple top-performing PRS based on each GWAS were combined through a linear or logistic regression in the fine-tuning sample. Final adjusted PRS weights were a linear combination of the top SNP weights from each GWAS, weighted by the regression coefficients. These combined

SNP weights were subsequently used to calculate PRS in the testing sample.

Conventionally, when fine-tuning polygenic risk scores (PRS) for a testing sample, it is ideal to use a sample from a matched or similar population. If such a sample is unavailable, the PRS can be fine-tuned using any available sample, which is often from individuals of European ancestry.

## Calculation of 1000 Genomes-based PCA and Euclidean

## distance

605

606 607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625 626

627

628

629

630

631

632

633

634 635

636 637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652 653

654

We use 1000 Genomes as the reference panel for PCA calculation. The PCA should be based on SNPs that are constantly included in as many samples as possible to enable the use of wide-ranging training and validation datasets. We started with the Hapmap3 SNPs for this set of SNPs, which has been widely used as a subset of SNPs that approximates the feature of genome-wide common SNPs in many recent studies that involve multi-ancestry prediction <sup>6,25,26,41</sup>. We further filtered for the SNPs likely to be frequently genotyped or imputed with relatively high quality by most samples based on the 1000 Genome data: Hapmap3 SNPs were first extracted from the five super-populations, Africans (AFR), Admixed Americans (AMR), East Asians (EAS), Europeans (EUR) and South Asians (SAS) of the 1000 Genomes. Secondly, SNPs described as the following were excluded: 1) of minor allele frequency lower than 1% in any of the super-population, 2) of minor allele frequency lower than 5% in the combined 1000 Genomes data, and 3) in the long-range LD region (25Mb – 35Mb by hg19 assembly on chromosome 6 and 7Mb – 13Mb on chromosome 8). To calculating the PCA loading, the QC'ed SNPs of the five super-populations were merged then pruned using the PLINK2 function "indep-pairwise" with the parameter "200 100 0.1" - namely the pruning was performed using window size = 200kb, step size = 100, and phased-hardcall- $r^2$ = 0.1. The principal components and the SNP loadings are calculated using PLINK2 function "pca" with the parameter "allele-wts" based on the pruned SNPs.

Based on the protocol suggested on the PLINK2 website (https://www.coggenomics.org/plink/2.0/score#pca project), we projected samples for fine-tuning and PRS testing into the PCA space as describe above by calculation the linear score, i.e. the sum of alternative alleles weighted by the SNP effect size, using the PLINK2 function "score" with the SNP loadings as effect size. The original online protocol suggested linear score should be first scaled to standard variation and then rescaled by multiplying the square root of eigenvalue. However, the actual standard deviation of a sample in the same PCA space varies with the homogeneity and the ancestry of the sample. Forcing the PCA of all the samples to have the same standard deviation will cause inconsistent scaling when the samples can be of different ancestries. Therefore, we directly calculated the PCA from sum basic linear score based on the SNP loadings as generated above without any further scaling. The PCA in this study was the sum basic linear score calculated using the PLINK2 function "score" with the parameter "cols=+scoresums". For large samples whose genotype data were divided into per-chromosome files, the same commands were used to calculate perchromosome score and the genome-wide score was the sum of the score of all the autosomes.

In DiscoDivas' default setting, the genetic distance between two individuals is defined as the Euclidian distance between the PCA of the two individuals. When the genetic

distance calculation involves a sample, we use the median point to present the whole sample.

We also explored the relationship between number of PCs included in the calculation and the Euclidean distance calculated (Supplementary Figure 9) and the distance calculated converged when the number of PCs was larger than 6 in our tests. In our analysis we use the top 10 PCs to calculate the PCs.

## Genetic ancestry reference

We noticed that the protocol of generating top PCs for ancestry references varied in previous publications. In our pilot test (see supplementary text section entitled 'Pilot test of generating PCA based on less QC'ed SNPs'), we compared the ancestry reference based on Hapmap3 SNP without any QC and found the result to be highly correlated. We used the same set of PCs based on QC'ed SNP as described in section 'Calculation of 1000 Genomes-based PCA and Euclidean distance' for both genetic ancestry reference and Euclidean distance calculation for data consistency.

Random forest model of 100 trees was trained based on the 1000 Genome data. The out-of-bag estimate of error rate stabilize at the level of 0.28% after the number of PCs passed 5. We used the model using the top 6 PCs to infer the genetic ancestry of UK Biobank individuals and the Mass General Brigham Biobank individuals. The genetic ancestry of an individual was assigned to any of the five ancestries represented in the 1000 Genomes reference data, i.e. AFR, AMR, EAS, EUR and SAS, if the highest probability of an individual belonging to that ancestry passed a threshold. If none of the ancestries had a probability above the threshold, the individuals were assigned as "to be decided" (tbd), which indicated that the individual was of admixed ancestries. With the consideration of the sample size and confirmed by visual inspection, the threshold of probability for UK Biobank and the Mass General Brigham Biobank was 0.9 and 0.8 respectively.

### Data

#### **UK Biobank**

The UK Biobank (UKBB) is a volunteer sample of approximately 500,000 adults aged 40-69 upon enrollment living in the United Kingdom recruited since 2006<sup>42</sup>. UKBB data used in this research were first QC'ed with the following process: Remove the individuals meeting the criteria that indicate low genotype quality or contamination: 1) have missing genotype rate larger than 0.02; 2) have genotype-phenotype sex discordance; 3) are identified as having excess heterozygosity and missing rates; 4) are identified as putatively carrying sex chromosome configurations that are not either XX or XY; 5) appeared to have unreasonably large numbers of relatives. From the remaining samples, individuals from a group of multiple individuals that are closer than 3<sup>rd</sup>-degree relatives were retained. 415,402 individuals were left after the QC. 390,037 were self-identified as EUR, 7,039 AFR, 8,652 non-Chinese Asian (ASN), 1430 Chinese (CHN) and 6572 unknown or not answered ("tbd"), and 1672 as admixed (MIX). The genetic ancestry referred from PC was largely correlated with the self-reported race, with 385,038 EUR, 7,450 AFR, 8,298 SAS, 2,163 EAS, 669 AMR and 11,784 admixed, or to-be-decided ("tbd").

In the PRS test, UKBB samples were grouped by their genetic ancestry (see section 'Genetic ancestry reference'). The validation datasets for the single-ancestry populations (AFR, EAS, EUR and SAS) were based on 1.3k randomly selected samples whose self-report ancestry matched with their genetic ancestry and the probability of random forest = 1. The validation dataset for admixed ancestry ("tbd") is 1.3k randomly selected samples of individuals of "tbd" genetic ancestry (see Supplementary Figure 3). AMR didn't have its corresponding validation dataset due to its small sample size and we used "tbd" validation datasets as a proxy since the two genetic ancestries had similar PCA. The remaining individuals of UKBB were used as testing data.

The quantitative trait of the UKBB samples was the measurement collected after the participants enrolled. The lipid trait measurement was adjusted for cholesterollowering medication by dividing TC by 0.8 and LDL by 0.7 as before<sup>43</sup>. Cases of coronary artery diseases (CAD) are defined using the definition described previously<sup>24</sup>: Cases of diabetes are defined as ever report the following code: E10X. E11X, E12X, E13X, and E14X where X can be any integer between 0 to 9 in the ICD10 diagnosis code.

UKBB participants provided consent in accordance with the primary IRB protocol, and the Massachusetts General Hospital IRB approved the present secondary data analysis of the UKBB data under UKBB application 7089.

#### Mass General Brigham Biobank

703

704

705

706

707

708

709

710

711

712

713 714

715

716

717

718

719

720

721 722

723

724

725 726

727

728 729

730

731

732 733

734

735

736 737

738 739

740

741

742

743

744

745

746

747

748

749

750

751

752 753 The Mass General Brigham Biobank (MGBB) is a volunteer sample of approximately 142,000 participants receiving medical care in the Mass General Brigham health care system recruited starting 2010. 53,306 MGBB participants underwent genotyping via Illumina Global Screening Array (Illumina, CA). MGBB genotype data was quality controlled, imputed and assigned one of the populations AFR, AMR, EAS, EUR, SAS using K-nearest neighbor model as described previously<sup>44</sup>. The phenotype data of CAD and diabetes are drawn from PheCodes based on International Classification of Diseases codes, Nineth (ICD9)110 and Tenth (ICD10) revisions, from the EHR as described previously<sup>32</sup>. MGBB participants provided consent in accordance with the primary IRB protocol, and the Massachusetts General Hospital IRB approved the present secondary data analysis.

#### All of Us Research Program

The All of Us (AoU) Research Program is a volunteer sample of more than one million United States residents recruited starting 2016. AoU aims to engage communities previously underrepresented in biomedical research in the United States and beyond<sup>45</sup>. In the present analysis, genetic data from the v7 245,394 participants who were genotyped using short read whole genome sequencing (srWGS) data. Hapmap3 SNPs were extracted for the callset with the threshold of (AF) > 1% or population-specific allele count (AC) > 100. Related individuals were pruned according to the information provided by AoU. Due to the inclusive data collection, we didn't excluded individuals whose self-report gender were different with their assigned sex at birth and used the combination of self-report gender and assigned sex as one of the covariates. The predicted ancestry information was provided by AoU<sup>46</sup>. The phenotypes were defined as described in previous research by Buu et al<sup>47</sup>.

#### Simulated data

To generate the simulated GWAS summary statistics, the genotype data was generated by Zhang et al<sup>6</sup> and downloaded from

https://dataverse.harvard.edu/dataverse/multiancestry. Only Hapmap3 SNPs were included in the simulation. Causal SNPs were randomly selected from the Hapmap3 SNPs and simulated per allele effect size following normal distribution. The ladder of causal SNP number was 100, 1000, 3000, 10000 and the heritability in each of the population was 0.6.

When simulated trait whose causal SNP effect size varied linearly in the PCA space, we first assumed that individuals whose PCA was the median point of the 1000 Genomes followed multivariate normal distribution with the covariance matrix being:

	EUR	SAS and EAS	AFR
EUR	1	0.7	0.4
SAS and EAS	0.7	1	0.7
AFR	0.4	0.7	1

Similar to the principle that PRS weight can be interpolated is equivalent to PRS can be interpolated, causal SNP effect size varies linearly in the PCA space and, therefore, can be interpolated is equivalent to genetic burden can be interpolated. The genetic burden of an individual is the weighted sum of what the genetic burden could be based on the simulated SNP effect size of the median point of each validation sample, with the weight proportion to the reciprocal of the PCA distance. We assumed that the non-genetic factor of individuals across different ancestries could be summed up as a quantitative variable independently drawn from the same normal distribution. The phenotype is the sum of genetic burden and non-genetic factor:

$$phenotype_i = \sum \beta_j x_{j,i} + E_i$$

where the  $phenotype_i$  and  $E_i$  were the phenotype and non-genetic factor of individual i;  $\beta_j$  was the effect size of causal SNP j, and  $x_{j,i}$  was the number of risk alleles of individual i in SNP j.

We used the PLINK2<sup>28</sup> to calculate the genetic burden based on the simulated causal SNPs and effect size and used R to simulate the non-genetic factors, scale the genetic burden and non-genetic factor, and generate a phenotype of heritability set to be 0.6. We used up to 100k individuals per population to generate the summary statistical GWAS as the discovery data for the PRS test. The rest simulated data were left out for the validation and testing datasets

In addition to the completely simulated data, we generated more realistic validation and testing datasets of a wider ancestry range by using the QC'ed genotype data from UKBB described in the section 'Biobank data.' While we used all the non-European testing data, the EUR testing dataset was down-sampled to 10,000 for the simulation test to reduce the computation burden. We simulated the genetic burden, non-genetic factor, and phenotype based on the real-life UKBB genotype data with the same pipeline and parameters. The simulated data based on UKBB genotype data were used as validation and testing data in the main test and left-out completely simulated data were used in the sensitivity test.

# **Acknowledgement**

799

803

804

812813

814

- We thank the participants and staff of the UK Biobank (application 7089), Mass
- 801 General Brigham Biobank, and All of Us Research Program. We thank Ying Wang,
- Paul O'Reilly, Raymond Walters for helpful discussion and advice.

# **Data and Code availability**

- The access to biobank data (UK Biobank, Mass General Brigham Biobank, and All of
- 806 US Research Program) were gained upon application. The simulated genotype data
- based on 1000 Genomes were downloaded from
- 808 <a href="https://dataverse.harvard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/COXHAP">https://dataverse.harvard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/COXHAP</a>
- 309 ; The resource of summary statistics GWAS data used to generate PRS were given
- in the supplementary file. The scripts of running DiscoDivas and other supporting
- 811 files can be found at <a href="https://github.com/YunfengRuan/DiscoDivas">https://github.com/YunfengRuan/DiscoDivas</a>

# Reference

- Martin, A. R. *et al.* Clinical use of current polygenic risk scores may exacerbate health disparities. *Nat Genet* **51**, 584–591 (2019).
- 817 2. Miao, J. *et al.* Quantifying portable genetic effects and improving cross-818 ancestry genetic prediction with GWAS summary statistics. *Nat Commun* **14**, 819 832 (2023).
- 820 3. Ruan, Y. *et al.* Improving polygenic prediction in ancestrally diverse populations. *Nat Genet* **54**, 573–580 (2022).
- Jin, J. et al. MUSSEL: Enhanced Bayesian Polygenic Risk Prediction
   Leveraging Information across Multiple Ancestry Groups. bioRxiv
   2023.04.12.536510 (2023) doi:10.1101/2023.04.12.536510.
- 5. Patel, A. P. *et al.* A multi-ancestry polygenic risk score improves risk prediction for coronary artery disease. *Nat Med* **29**, 1793–1803 (2023).
- 827 6. Zhang, H. *et al.* A new method for multiancestry polygenic prediction improves performance across diverse populations. *Nat Genet* **55**, 1757–1768 (2023).
- Ding, Y. *et al.* Polygenic scoring accuracy varies across the genetic ancestry continuum. *Nature* **618**, 774–781 (2023).
- 8. Landry, L. G., Ali, N., Williams, D. R., Rehm, H. L. & Bonham, V. L. Lack Of Diversity In Genomic Databases Is A Barrier To Translating Precision Medicine Research Into Practice. *Health Aff* **37**, 780–785 (2018).
- The All of Us Research Program Genomics Investigators. Genomic data in the All of Us Research Program. *Nature* **627**, 340–346 (2024).
- 836 10. Fatumo, S. *et al.* Polygenic risk scores for disease risk prediction in Africa: current challenges and future directions. *Genome Medicine* vol. 15 Preprint at https://doi.org/10.1186/s13073-023-01245-9 (2023).
- Dokuru, D. R., Horwitz, T. B., Freis, S. M., Stallings, M. C. & Ehringer, M. A. South Asia: The Missing Diverse in Diversity. *Behav Genet* **54**, 51–62 (2024).
- Stefflova, K. *et al.* Dissecting the Within-Africa ancestry of populations of African descent in the Americas. *PLoS One* **6**, (2011).

- Harlemon, M. *et al.* A custom genotyping array reveals population-level heterogeneity for the genetic risks of prostate cancer and other cancers in Africa. *Cancer Res* **80**, 2956–2966 (2020).
- Anagnostou, P. *et al.* Inter-individual genomic heterogeneity within European population isolates. *PLoS One* **14**, (2019).
- 848 15. Pan, Z. & Xu, S. Population genomics of East Asian ethnic groups. *Hereditas* vol. 157 Preprint at https://doi.org/10.1186/s41065-020-00162-w (2020).
- Khera, A. V *et al.* Whole-Genome Sequencing to Characterize Monogenic and
   Polygenic Contributions in Patients Hospitalized With Early-Onset Myocardial
   Infarction. *Circulation* 139, 1593–1602 (2019).
- Duncan, L. *et al.* Analysis of polygenic risk score usage and performance in diverse human populations. *Nat Commun* **10**, 3328 (2019).
- Wang, M. *et al.* Validation of a Genome-Wide Polygenic Score for Coronary Artery Disease in South Asians. *J Am Coll Cardiol* **76**, 703–714 (2020).
- Here the second second
- O'Sullivan, J. W. et al. Polygenic Risk Scores for Cardiovascular Disease: A
   Scientific Statement From the American Heart Association. Circulation vol. 146
   E93–E118 Preprint at https://doi.org/10.1161/CIR.000000000001077 (2022).
- Lewis, C. M. & Vassos, E. Polygenic risk scores: From research tools to clinical instruments. *Genome Medicine* vol. 12 Preprint at https://doi.org/10.1186/s13073-020-00742-5 (2020).
- Xiang, R. et al. Recent advances in polygenic scores: translation, equitability,
   methods and FAIR tools. *Genome Medicine* vol. 16 Preprint at
   https://doi.org/10.1186/s13073-024-01304-9 (2024).
- Truong, B. *et al.* Integrative polygenic risk score improves the prediction accuracy of complex traits and diseases. *Cell Genomics* **4**, (2024).
- Wang, Y. *et al.* Polygenic prediction across populations is influenced by ancestry, genetic architecture, and methodology. *Cell Genomics* **3**, (2023).
- Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A. & Smoller, J. W. Polygenic
  prediction via Bayesian regression and continuous shrinkage priors. *Nat Commun* 10, 1776 (2019).
- 875 26. Privé, F., Arbel, J. & Vilhjálmsson, B. J. LDpred2: better, faster, stronger.
  876 Bioinformatics 36, 5424–5431 (2021).
- 27. Chang, C. C. *et al.* Second-generation PLINK: Rising to the challenge of larger and richer datasets. *Gigascience* **4**, (2015).
- 879 28. Auton, A. *et al.* A global reference for human genetic variation. *Nature* **526**, 880 68–74 (2015).
- 881 29. Atkinson, E. G. *et al.* Tractor uses local ancestry to enable the inclusion of admixed individuals in GWAS and to boost power. *Nat Genet* **53**, 195–204 (2021).
- 884 30. Sun, Q. *et al.* Improving polygenic risk prediction in admixed populations by explicitly modeling ancestral-differential effects via GAUDI. *Nat Commun* **15**, (2024).
- 887 31. Marnetto, D. *et al.* Ancestry deconvolution and partial polygenic score can improve susceptibility predictions in recently admixed individuals. *Nat Commun* **11**, (2020).
- Xu, Y. et al. Effect of Pathway-Specific Polygenic Risk Scores for Alzheimer's
   Disease (AD) on Rate of Change in Cognitive Function and AD-Related
   Biomarkers Among Asymptomatic Individuals. *Journal of Alzheimer's Disease*
- **94**, 1587–1605 (2023).
- Tubbs, J. D. *et al.* Pathway-Specific Polygenic Scores Improve Cross-Ancestry
   Prediction of Psychosis and Clinical Outcomes. Preprint at

- 896 https://doi.org/10.1101/2023.09.01.23294957 (2023).
- 897 34. Miao, J. *et al.* Quantifying portable genetic effects and improving cross-898 ancestry genetic prediction with GWAS summary statistics. *Nat Commun* **14**, 899 (2023).
- 900 35. Kumar, R., Bhattacharya, S. & Murmu, G. Exploring Optimality of Piecewise 901 Polynomial Interpolation Functions for Lung Field Modeling in 2D Chest X-Ray 902 Images. *Front Phys* **9**, (2021).
- 903 36. Womersley, R. S. & Sloan, I. H. How Good Can Polynomial Interpolation on the Sphere Be? Advances in Computational Mathematics vol. 14 (2001).
- 905 37. Choudhury, A. *et al.* Population-specific common SNPs reflect demographic histories and highlight regions of genomic plasticity with functional relevance. *BMC Genomics* **15**, (2014).
- 908 38. Rees, J. S., Castellano, S. & Andrés, A. M. The Genomics of Human Local 909 Adaptation. *Trends in Genetics* vol. 36 415–428 Preprint at 910 https://doi.org/10.1016/j.tig.2020.03.006 (2020).
- 911 39. Mas-Sandoval, A., Mathieson, S. & Fumagalli, M. The genomic footprint of social stratification in admixing American populations. **12**, 84429 (2023).
- 913 40. Patel, R. A. *et al.* Genetic interactions drive heterogeneity in causal variant effect sizes for gene expression and complex traits. *Am J Hum Genet* **109**, 1286–1297 (2022).
- 916 41. Yengo, L. *et al.* A saturated map of common genetic variants associated with human height. *Nature* **610**, 704–712 (2022).
- 918 42. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203–209 (2018).
- 920 43. Graham, S. E. *et al.* The power of genetic diversity in genome-wide association studies of lipids. *Nature* **600**, 675–679 (2021).
- 922 44. Koyama, S. *et al.* Decoding Genetics, Ancestry, and Geospatial Context for Precision Health. *medRxiv* (2023) doi:10.1101/2023.10.24.23297096.
- 45. Kathiresan, N. et al. Representation of Race and Ethnicity in the
   Contemporary US Health Cohort All of Us Research Program. JAMA Cardiol
   8, 859–864 (2023).
- 927 46. Bick, A. G. *et al.* Inherited causes of clonal haematopoiesis in 97,691 whole genomes. *Nature* **586**, 763–768 (2020).
- 929 47. Truong, B. *et al.* Integrative polygenic risk score improves the prediction accuracy of complex traits and diseases. *medRxiv* (2023) doi:10.1101/2023.02.21.23286110.

# **Supplementary Figures**

934

935

936

937


938


939 940


941


944

Supplementary Figure 1: Comparison of PRS R<sup>2</sup> of conventional PRS method and DiscoDivas when the validation dataset for the conventional method were of the matched ancestry with the testing dataset. The four subplots correspond to the four simulated scenarios of different discovery GWAS sample size and causal SNP effect size shown in the 4 panels in Figure 2. Within each subplot, each panel shows the performance of the two methods in each testing sample; the color of the datapoints showed the number of causal SNPs simulated.













Supplementary Figure 2: The relative increase PRS R² of DiscoDivas over conventional PRS method. The four subplots correspond to the four simulated scenarios of different discovery GWAS sample size and causal SNP effect size shown in the 4 panels in Figure 2. Within each subplot, each panel shows the performance of the two methods in each combination of validation sample for the conventional PRS method and the testing sample; the horizontal bar show the mean value of the relative increase; the color of the horizontal bar indicating mean value of relative increase and p-value of the paired t-test of DiscoDivas PRS R² and conventional PRS R², with cyan being the mean increase>0 and p-value<0.005, dark blue being mean increase>0 and p-value<0.05, and grey being p-value>0.05












#### Supplementary Figure 3: The comparison of PCA of UKBB validation sample and the 1000 Genomes reference.







 Supplementary Figure 4: The comparison of PCA distance between the testing individual and the median point of validation samples when using the actual value of UKBB validation samples and the approximated value of using the 1000 Genomes sample. Each column of the panels shows the ancestry of testing individuals, and each row of the panels shows the distance to the validation samples. The range of the distance to median point of the validation samples shows in the lower edge of the panel, with the blue color indicating the range of distance based on actual UKBB validation sample and the red color indicating the range of distance based on 1000 Genomes approximate. The correlation of the two sets of calculated distance is shown in each panel.




 Supplementary Figure 5: The comparison of the interpolation combination coefficient when using the actual value of UKBB validation samples and the approximated value of using the 1000 Genomes sample. Each column of the panels shows the ancestry of testing individuals, and each row of the panels shows validation sample for which the interpolation combination coefficient is for. The range of interpolation combination coefficients shows in the lower edge of the panel, with the blue color indicating the range of combination coefficients based on actual UKBB validation sample and the red color indicating the range of combination coefficients based on 1000 Genomes approximate. The correlation of the two sets of combination coefficients is shown in each panel.



Supplementary Figure 6: The comparison of DiscoDivas PRS R<sup>2</sup> when using the actual value of UKBB validation samples and the approximated value of using the 1000 Genomes sample. Each column of the panels shows the ancestry of testing individuals, and each row of the panels shows the simulated number of causal SNPs. The four subplots correspond to the four simulated scenarios of different discovery GWAS sample size and causal SNP effect size shown in the 4 panels in Figure 2.





Supplementary Figure 7 Comparison of PRS  $\ensuremath{\mathsf{R}}^2$  of using UKBB-based validation sample and using the purely simulated validation sample. The upper subplot shows the results of conventional PRS method and the lower shows the result of DiscoDivase

1012 1013

1014

1015


1016


1017 1018

1019

1020 1021

Within each subplot, the column of panels and the color of the datapoints shows the testing sample and the row of the panels shows the simulated number of causal SNPs;





Supplementary Figure 8: The relative increase PRS R<sup>2</sup> of DiscoDivas over conventional PRS method when using the purely simulated validation data. Each panel shows the performance of the two methods in each combination of validation sample for the conventional PRS method and the testing sample; the horizontal bar show the mean value of the relative increase; the color of the horizontal bar indicating mean value of relative increase and p-value of the paired t-test of DiscoDivas PRS R<sup>2</sup> and conventional PRS R<sup>2</sup>, with cyan being the mean increase>0 and p-value<0.0005, dark blue being mean increase>0 and p-value<0.05, dark red being mean increase<0 and p-value<0.05, and grey being p-value>0.05

1024

1025 1026


1027

1028 1029

1030

1031 1032

1033



Supplementary Figure 9: The PRS distance between individuals in testing samples to the median point of the validation samples when including different numbers of PCA in the distance calculation. Each panel shows the ancestry of the testing samples and the color of the line shows the validation samples to which the distance is calculated. The plot is based on 100 randomly selected individuals from each UKBB testing sample.

1036

1037

1038

1039

1040

1041

1042 1043

